Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 19/20 | 1.00 |
| ▸ | CYSLTR1 | Q9Y271 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | EGFR | P00533 | 1/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.74 |
| ▸ | FYN | P06241 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200470 | 1.00 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1MEN1RECQLBLM | |
| SCHEMBL5200473 | 1.00 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1MEN1RECQLBLM | |
| SCHEMBL8127534 | 0.94 | CYSLTR2 (0.88) | CYSLTR2CYSLTR1MEN1RECQLBLM | |
| SCHEMBL9250136 | 0.94 | CYSLTR2 (0.88) | CYSLTR2CYSLTR1MEN1RECQLBLM | |
| SCHEMBL8122391 | 0.94 | CYSLTR2 (0.88) | CYSLTR2CYSLTR1MEN1RECQLBLM | |
| SCHEMBL9255522 | 0.94 | CYSLTR2 (0.88) | CYSLTR2CYSLTR1MEN1RECQLBLM | |
| SCHEMBL8122390 | 0.94 | CYSLTR2 (0.88) | CYSLTR2CYSLTR1MEN1RECQLBLM | |
| SCHEMBL8127536 | 0.94 | CYSLTR2 (0.88) | CYSLTR2CYSLTR1MEN1RECQLBLM | |
| SCHEMBL7162733 | 0.90 | CYSLTR2 (0.84) | CYSLTR2CYSLTR1 | |
| SCHEMBL9390495 | 0.90 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404715-B2 | Methods and compositions using racemic, (R)-, and (S)-fexofenadine in combination with leukotriene inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | claimed |
| US-20120149730-A1 | METHODS AND COMPOSITIONS USING RACEMIC, (R)-, AND (S)-FEXOFENADINE IN COMBINATION WITH LEUKOTRIENE INHIBITORS | RUBIN PAUL D (US) | 2012-06-14 | — | — | US | claimed |
| EP-1707216-A1 | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors | Sepracor Inc. (US) | 2006-10-04 | — | — | EP | claimed |
| EP-1071463-B1 | METHODS AND COMPOSITIONS USING TERFENADINE METABOLITES IN COMBINATION WITH LEUKOTRIENE INHIBITORS | SEPRACOR INC (US) | 2006-06-07 | — | — | EP | claimed |
| US-6790849-B2 | Methods and compositions using optically pure (-) cetirizine in combination with leukotriene inhibitors or decongestants | SEPRACOR INC. | 2004-09-14 | — | — | US | claimed |
| US-20030083343-A1 | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors | SEPRACOR INC. | 2003-05-01 | — | — | US | claimed |
| US-20020099058-A1 | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants | SEPRACOR INC. (US) | 2002-07-25 | — | — | US | claimed |
| US-20020086854-A1 | For treatment or prevention of inflammation or allergic disorders, such as asthma | SEPRACOR, INC. | 2002-07-04 | — | — | US | claimed |
| US-6372197-B1 | Methods and compositions using norastemizole in combination with leukotriene inhibitors | SEPRACOR INC. | 2002-04-16 | — | — | US | claimed |
| US-6248308-B1 | Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma | SEPRACOR INC. | 2001-06-19 | — | — | US | claimed |
| US-6194431-B1 | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors | SUNOVION PHARMACEUTICALS INC. | 2001-02-27 | — | — | US | claimed |
| EP-1071463-A1 | METHODS AND COMPOSITIONS USING TERFENADINE METABOLITES IN COMBINATION WITH LEUKOTRIENE INHIBITORS | SEPRACOR, INC. (US) | 2001-01-31 | — | — | EP | claimed |
| WO-1999052554-A1 | METHODS AND COMPOSITIONS USING TERFENADINE METABOLITES IN COMBINATION WITH LEUKOTRIENE INHIBITORS | SEPRACOR INC. (US) | 1999-10-21 | — | — | WO | claimed |
| US-8404715-B2 | Methods and compositions using racemic, (R)-, and (S)-fexofenadine in combination with leukotriene inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120149730-A1 | METHODS AND COMPOSITIONS USING RACEMIC, (R)-, AND (S)-FEXOFENADINE IN COMBINATION WITH LEUKOTRIENE INHIBITORS | RUBIN PAUL D (US) | 2012-06-14 | — | — | US | disclosed |
| EP-1819329-A2 | PHARMACEUTICAL FORMULATIONS COMPRISING PLECONARIL FOR THE TREATMENT OF AIRWAY DISEASES | Schering Corporation (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1069124-A1 | 2-Benzimidazolylamine compounds as ORL1-receptor agonists | PFIZER INC. (US) | 2001-01-17 | — | — | EP | disclosed |
| US-5472964-A | Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1995-12-05 | — | — | US | disclosed |
| WO-1995018132-A1 | DIARYL 5,6-FUSED HETEROCYCLIC ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1995-07-06 | — | — | WO | disclosed |
| WO-1994014815-A1 | DIARYL 5,6-FUSEDHETEROCYCLIC ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1994-07-07 | — | — | WO | disclosed |